Literature DB >> 11798503

Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants.

G Zecchina1, D Novick, M Rubinstein, V Barak, C Dinarello, A Nagler.   

Abstract

Dysregulation of the cytokine network plays an important role in graft-versus-host disease (GVHD). Interleukin-18 (IL-18) is an obligatory cytokine for interferon-gamma (IFN-gamma) production and IFN-gamma and sIFN-gammaR are elevated in patients with GVHD. Because IL-18 binding protein (IL-18BP) is an inhibitor of IL-18-mediated IFN-gamma production, we evaluated IL-18BP levels in patients undergoing allogeneic peripheral blood stem cell transplantation (PBSCT). IL-18BP levels were assessed in 14 patients on day -10 (before conditioning), on the day of transplant, on the day of engraftment, and during transplant-related complications. A comparison of the kinetics of IL-18BP and soluble(s) IL-6R, sIFN-gammaR, IL-18 serum levels was performed. IL-18BP levels were assessed by specific monoclonal antibodies in a double-sandwich enzyme-linked immunosorbent assay (ELISA). In all patients IL-18BP levels decreased during conditioning and increased in parallel with engraftment (p < 0.05). Accordingly, during rejection, IL-18BP serum levels remained low and similar to pretransplant levels. The mean elevation of IL-18BP detected in association to acute GVHD was significantly higher in comparison to normal engraftment (p < 0.05). A correlation between IL-18BP, sIFNgammaR, and sIL-6R serum levels was found in all patients. No correlation between IL-18 and IL-18BP serum levels was found in patients undergoing uneventful PBSCT and rejection, whereas a marked increase in both IL-18 and IL-18BP levels was detected during acute GVHD (p < 0.01). Our data suggest that the dysregulation of IL-18 and IL-18BP may be important in the pathophysiology of transplant-related complications. Furthermore, because preliminary data from our group show that IL-18 blockage ameliorates GVHD in murine models, it is inferred that these cytokines may represent potential targets in the development of new therapeutic strategies in acute GVHD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11798503     DOI: 10.1089/152581601317210863

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  7 in total

1.  Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients.

Authors:  K Manohar; P V Suneetha; Nirupama Trehan Pati; Abhishek C Gupta; Syed Hissar; Puja Sakhuja; S K Sarin
Journal:  Hepatol Int       Date:  2009-03-17       Impact factor: 6.047

2.  Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation.

Authors:  Menachem Bitan; Lola Weiss; Michael Zeira; Eyal Zcharia; Shimon Slavin; Arnon Nagler; Israel Vlodavsky
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

3.  Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation.

Authors:  Sebastian Scholl; Herbert G Sayer; Lars-Olof Mügge; Christoph Kasper; Marko Pietraszczyk; Kay-Oliver Kliche; Joachim H Clement; Klaus Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-07       Impact factor: 4.553

Review 4.  Role of viral and host factors in interferon based therapy of hepatitis C virus infection.

Authors:  Muhammad Imran; Sobia Manzoor; Javed Ashraf; Madiha Khalid; Muqddas Tariq; Hafiza Madeha Khaliq; Sikandar Azam
Journal:  Virol J       Date:  2013-10-01       Impact factor: 4.099

Review 5.  Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.

Authors:  Abdulraouf Ramadan; Sophie Paczesny
Journal:  Front Immunol       Date:  2015-01-28       Impact factor: 7.561

6.  Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study.

Authors:  Aleksandar Radujkovic; Lambros Kordelas; Hao Dai; David Schult; Joshua Majer-Lauterbach; Dietrich Beelen; Carsten Müller-Tidow; Peter Dreger; Thomas Luft
Journal:  EBioMedicine       Date:  2019-11-01       Impact factor: 8.143

Review 7.  Interleukin 18 gene promoter polymorphisms and susceptibility to chronic hepatitis B infection: a review study.

Authors:  Mahsa Motavaf; Saeid Safari; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2014-07-01       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.